Kornimate/medical-research-clean huggingface dataset:
association of plasma biomarkers for neurological injury and postoperative delirium after cardiac surgery

Conditions: Postoperative Delirium

Summary: delirium is one of the most common complications after cardiac surgeries, incidence of which is 20\~70%. causes and pathophysiology of delirium has not been elucidated yet, however, inflammatory response of the nervous system, imbalance of neurotransmitters and ischemia-reperfusion injury of brain tissue are thought to play a big role. 'neurofilament light (nfl)' and 'tau' are proteins that comprise neurons, which are released into blood during acute brain injury. increased serum concentrations of these markers are acknowledged to be associated with worse clinical outcomes in patients with acute brain injury. these proteins are also closely linked to degenerative changes in the nervous system and cognitive decline in alzheimer's disease. therefore, the increase in blood levels of 'nfl' and 'tau' may be related to the development of delirium. the aim of this study is to investigate the association between 'nfl' and 'tau', serum markers of damage of the nervous system, and the development of delirium after cardiac surgery.

1. assessment of cognitive function and delirium before the day before surgery, k-mmse (korean version of mini-mental state exam) is conducted to check the subjects' baseline cognitive function. from the postoperative day 0 to 7, cam-icu (confusion assessment method for the intensive care unit) for mechanically ventilated patients, or 3d-cam (3-minute diagnostic assessment for delirium using the confusion assessment method) for extubated patients is performed twice a day to assess whether delirium occurs. records of the nurses are also checked. 2. measurement of the serum levels of nfl and tau serum concentrations of nfl and tau are measured after anesthetic induction, and at postoperative 6 hours

Eligibility criteria:
inclusion criteria: * 1. patients undergoing valvular heart surgery (\>65 years old) exclusion criteria: * 1. emergency operation * 2. patients with drug or alcohol abuse * 3. patients with major depressive disorder, major neurocognitive disorder or schizophrenia * 4. patients with schizophrenia * 5. patients who are not able to communicate verbally

Keywords: neurofilament light tau delirium valvular heart surgery
evaluating the impact of a technologically-enhanced personal coaching program on hemoglobin a1c in type 2 diabetics

Conditions: Diabetes Mellitus

Summary: participants diagnosed with type 2 diabetes receive personal coaching from a certified diabetic educator (cde) over a six-month period. the coaching program is enhanced using an mobile application and care management platform.

participants diagnosed with type 2 diabetes receive personal coaching from a certified diabetic educator (cde) over a six-month period. the coaching program is enhanced by integrating a participant-facing mobile application with the coaching platform. blood glucose test results automatically populate the coaching platform, providing the cde with information that may better support their coaching efforts. the participants complete diabetes self management education (dsme) learning modules for the first 7-12 weeks. following completion of the modules, the coach continues to provide support to the participant until 24 weeks after the participant's enrollment.

Eligibility criteria:
inclusion criteria: * lives in the united states * speaks and understands english * has a type 2 diabetes mellitus diagnosis * has a lifescan verio flex blood glucose meter, which is connected to onetouch reveal ® app * has a verified a1c ≥ 8% * willing to participate in coaching program exclusion criteria: * uses a continuous glucose monitoring device * currently pregnant * unable to make lifestyle behavioral changes due to a cognitive or physical disability * has end stage renal disease (esrd) diagnosis * is not able to read or understand english
efficacy of agomelatine in patients with obsessive-compulsive disorder

Conditions: Obsessive Compulsive Disorder

Summary: the study will evaluate the efficacy of agomelatine compared to placebo on the reduction of obsessive and compulsive symptoms after 16 weeks of treatment.


Eligibility criteria:
inclusion criteria: * obsessive compulsive disorder (ocd) according to diagnostic and statistical manual, fourth edition, text revision (dsm-iv-tr), * y-bocs total score ≥ 20, * duration of ocd symptoms of at least one year. exclusion criteria: * bipolar disorder, schizophrenic or psychotic disorder * severe or uncontrolled organic diseases * neurological disorder * women of childbearing potential who are not using effective contraception

Keywords: obsessive compulsive disorder agomelatine
panoramic screening by complete colonoscopy in the management of colorectal adenomas

Conditions: Colorectal Adenoma

Summary: colonoscopy is the gold standard for colorectal cancer prevention by allowing the resection of superficial colorectal adenomas or adenocarcinomas. this protection, more effective in the left colon than in the right colon, is imperfect and there are some adenomas and cancers omitted during colonoscopy. the g-eye colonoscope equipped with an integrated distal balloon would better unfold the haustrations and stabilize the endoscope. thus, the detection rate of adenomas would be improved by this better vision. the main objective of this study is to confirm that the use of the g-eye colonoscope allows better detection of adenomatous polyps, decrease the rate of omitted adenomes and then is more effective.


Eligibility criteria:
inclusion criteria: 1. indication of complete colonoscopy for classic indications (bleeding, abdominal pain, transit disorders) or for family and personal antecedents of adenomas or colorectal cancers with the need for endoscopic control, 2. fit + test (current blood test for stool used for mass screening in france), pet-ct fixation, 3. consent of participation signed, 4. affiliation to a social security scheme, or beneficiary of such a scheme. exclusion criteria: 1. non-optimal preparation (boston score \<7 or segment \<2), 2. adenomatous polyposis, familial or assimilated (juvenile, etc.), 3. pregnant or likely to be pregnant (without effective contraception) or breastfeeding, 4. patient in emergency or deprived of liberty or placed under the authority of a tutor, 5. patient considered geographically socially or psychologically unable to comply with the study procedure and the medical follow-up.

Keywords: colonoscopy g-eye adenomas
guanfacine treatment for prefrontal cognitive dysfunction in elderly subjects

Conditions: Cognitive Aging

Summary: this proposal aims to determine whether low does of the alpha-2a-adrenoceptor agonist guanfacine can improve deficits in prefrontally-mediated cognitive functions in healthy elderly subjects.

primary: * to determine whether low does of the α2a-adrenoceptor agonist guanfacine can improve deficits in prefrontally-mediated working memory and executive control functions, in healthy elderly subjects. subjects will be randomly assigned to receive placebo or guanfacine at one of two dose levels: 0.1 mg, or 0.5 mg daily at bedtime in double-blind fashion for twelve weeks. secondary: * to determine whether guanfacine can favorably influence global status and quality of life (qol) in healthy elderly subjects. * to determine whether low-dose guanfacine is safe and well-tolerated in healthy elderly subjects.

Eligibility criteria:
inclusion criteria: subjects enrolled will be nondemented, male and female individuals who meet the following inclusion criteria: * 75 years of age or older * fluent in english * stable medical condition for at least 4 weeks prior to screening visit * stable dose of non-excluded medications for at least 4 weeks prior to screening visit exclusion criteria: * dementia * mild cognitive impairment (amnestic mci) * clinically significant neurologic disease * clinically significant or unstable medical conditions that would interfere with participation in the trial * known hypersensitivity to guanfacine * history of alcohol or substance abuse or dependence within the past 5 years * active major psychiatric disorders, including major depression * history of mental retardation * significant abnormalities on clinical laboratories, ecg, or physical examination * impairment of visual or auditory acuity sufficient to interfere with completion of study procedures * education level \< 6 years

Keywords: guanfacine aging cognitive aging prefrontal cognitive function executive function prefrontal cortex
alcohol pbs and thinking about the past

Conditions: Alcohol Drinking in College

Summary: individuals often think of how a situation or outcome could have turned out differently -- if only something was different or something had changed, then the outcome could have been better or worse. this is a common type of thinking, known as counterfactual thinking, that often takes the form of "if only" statements. these thoughts are frequent after negative events, but have also been found to occur after positive events and 'near misses'. research has shown that their evaluative nature elicits a variety of consequences, such as biased decision making, changes in an event's meaningfulness, heightened positive or negative affect, and future behavioral changes (such as intentions, motivation, persistence/effort. specifically, many areas of research involving counterfactuals have often looked into key elements that are often discussed in other health behavior literature, such as self-efficacy, motivation, and intentions. one such area that incorporates these elements is health promotion literature, such as protective behavioral strategies (pbs) and alcohol consumption. the objectives of this study are laid out as such: first, to further explore the role counterfactuals play in increasing an individual's intentions toward behavioral change. second, to further elucidate the inner and outer workings of protective behavioral strategies for increasing positive health behaviors. finally, to address the applicability of a counterfactual intervention on promoting intentions to use pbs.


Eligibility criteria:
inclusion criteria: * minimum age of 18 years exclusion criteria: * no exclusions at baseline * participants who do not follow the instructions for the specific writing task will be unable to sign-up for the remaining follow up sessions (parts 2-6) and will be excluded the final data analyses
transgender and gender diverse individuals screening for breast cancer

Conditions: Breast Cancer

Summary: the goal of this multicentric prospective study is to evaluate the incidence of breast cancer in transgender and gender-diverse population.

in recent years, the scientific community has been paying increasing attention to lesbian, gay, bisexual, transgender, queer, intersexual, asexual population, with a special focus on transgender and gender-diverse individuals. globally, the percentage of adults who identify themselves as transgender varies between 0.3% and 0.5%, while approximately 0.5% to 4.5% of adults are estimated to identify as gender-diverse. despite the growing visibility of transgender and gender-diverse community and the efforts towards their depathologization, healthcare still needs to address two fundamental issues: the inadequate preparation of healthcare staff regarding gender incongruence which results in mistreatment and discrimination and the lack of uniform and large-scale prospective data. scientific evidence regarding the risk of developing breast cancer (bc) in these patients and the related benefits of bc screening are still limited and insufficient. the associazione italiana di oncologia medica (aiom), reported that the risk of developing bc tends to increase in transgender women compared to cisgender men (standardized incidence ratio \[sir\], 46.7; 95% ci, 27.2-75.4), although it does not reach the level of risk in cisgender women (sir, 0.3; 95% ci, 0.2-0.4). conversely, in transgender men, the risk of bc decreases when compared to cisgender women (sir, 0.2; 95% ci, 0.1-0.5), but it still remains higher than the risk present in cisgender men (58.9; 95% ci, 18.7-142.2).as for the screening programs, there is a lower adherence among the transgender and non-conforming-gender population compared to the cisgender population, due to socio-economic barriers and a lack of clear recommendations supported by scientific evidence.the national comprehensive cancer network (nccn)and aiom guidelines currently do not include specific recommendations for transgender individuals due to the aforementioned lack of scientific evidence. the american college of radiology (acr) regulates screening protocols for the transgender population based on factors such as age, hormone therapy exposure, surgical history, and risk categories.

Eligibility criteria:
inclusion criteria: * transgender and gender-diverse individuals ≥18 years old who meet the acr inclusion criteria * signed informed consent exclusion criteria: * refuse to sign informed consent
study of platelet rich plasma drops to moderate clinically significant dry eye

Conditions: Dry Eye Syndromes

Summary: this is a single center double-masked study with up to four visits. subjects who have been diagnosed with dry-eye syndrome at flaum eye institute will be enrolled. the purpose of the study is to determine if using platelet rich plasma drops can improve clinically significant dry eye in patients and determine if there is a difference with using two different uses of the plasma tear drops: platelet rich plasma tears and plasma tears without platelets.


Eligibility criteria:
inclusion criteria: * subjects must be diagnosed with clinically significant dry eye. * subjects have no active ocular disease or allergic conjunctivitis. * subjects must not be using any topical ocular medications within two weeks prior to enrollment. * subjects must be willing and able to follow instructions. * subjects must have voluntarily agreed to participate in the study by signing the statement of informed consent. * subjects must meet plasma donor criteria as established by university of rochester transfusion medicine \& blood bank. exclusion criteria: * is pregnant at the time of enrolment in the study determined by urine pregnancy test. * is currently on a course of antibiotics * is considered by the investigator to not be a suitable candidate for participation and are not at risk for glaucoma. * is considered by the university of rochester transfusion medicine \& blood bank not a suitable candidate for blood donation.
effectiveness of vedolizumab in cd patients naïve to anti-tnf

Conditions: Crohn Disease

Summary: anti-cytokine antibodies, such as infliximab (an anti tnf alfa chimeric antibody) and adalimumab (an anti tnf alfa humanize antibody), have been developed and used in clinical practice for the treatment of patients with crohn disease (cd). unfortunately, their efficacy is limited. based on these concepts, a new drug has been developed for ibd treatment. vedolizumab (vdz) is able to recognize the α4β7 heterodimer, and selectively blocks gut lymphocyte trafficking. the hypothesis of this study is that vdz therapy may be to halt cd disease progression during time and modifying its natural history, using lemann index.

all patients who will enter in the study will be follow-up at weeks 2-6-14-22-30-38-46 or before in case of relapse. a relapse will be defined by an harvey bradshaw index ≥ 5 for 2 consecutive weeks. the following data are to be recorded: 1. physical examination 2. adverse event review 3. weight in kg 4. full blood count 5. biochemical series including serum iron, serum ferritin, c reactive protein (pcr), esr (eritrosedimatation rate) 6. fecal calprotectin 7. vdz fecal loos 8. vdz trough levels and antidrug antibodies 9. current treatments the last visit will be performed at week 54. the following data are to be recorded: 1. physical examination 2. adverse event review 3. weight in kg 4. full blood count 5. biochemical series including serum iron, serum ferritin, c reactive protein (pcr), esr (eritrosedimatation rate) 6. fecal calprotectin 7. vdz fecal loos 8. vdz trough levels and antidrug antibodies 9. current treatments 10. routine lower and upper gastrointestinal endoscopy and magnetic resonance imaging or computed tomography of the small bowel 11. ses-cd 12. lemann index

Eligibility criteria:
inclusion criteria: * have given written informed consent to participate * be aged between 18 and 80 * have a moderate/severe cd defined by an hbi \>7 cd exclusion criteria: * previous treatment with anti-tnf drugs, * concomitant use of immune-modulator drugs for cd (azathioprine/6-mercaptopurine, methotrexate) * ulcerative colitis (uc) or inflammatory bowel disease undetermined (ibd-u) diagnosis * symptomatic obstructive disease * bowel resection within the past 6 months * ileostomy * extensive small bowel resection (as determined by the investigator) or a short bowel syndrome * patients who are currently receiving total parenteral nutrition * history of cancer in the past 5 years * pregnancy known at the study inclusion * positive clostridium difficile stool assay * listeria, human immunodeficiency virus, central nervous system demyelinating disease, untreated tuberculosis
effect of vitamin d supplementation as adjuvant therapy in neonatal jaundice in combination with phototherapy

Conditions: Neonatal Jaundice

Summary: neonatal jaundice frequently occur during initial week of life. neonatal jaundice is one of the leading causes of hospital admission and readmission. some studies have suggested that the healthy newborns with hyperbilirubinemia outside the physiological range have notably reduced serum vitamin d levels. this deficiency is inversely associated with neonatal hyperbilirubinemia, suggesting that low vitamin d levels could be a potential risk factor for jaundice among neonates.


Eligibility criteria:
inclusion criteria: * both genders * admitted between 3-28 days of age. * indirect hyperbilirubinemia with tsb levels between 14-20 mg/dl * born via either cesarean or vaginal delivery * birth weight greater than 2500 grams exclusion criteria: * prior phototherapy treatment * preterm birth (gestational age below 37 weeks). * spo2 \< 95% at the time of admission * severe respiratory distress or failure * neonatal sepsis * congenital anomalies * parents/guardians unwilling to let their neonates be part of this study.
are we loading our patients with sodium during hemodialysis treatments?

Conditions: Renal Failure

Summary: the objectives of the data search is to find out if there is correlation between pre, post serum sodium concentration, dialysate sodium concentration, interdialytic weight gain and associated changes in pre and post systolic and diastolic blood pressure, mean arterial pressure, number of blood pressure medications and adherence to 3 times per week dialysis, mortality.


Eligibility criteria:
inclusion criteria: * hemodialysis patient
safety, tolerability, and pharmacokinetics of a single dose of nbi-98854 in subjects with mild,moderate, or severe hepatic insufficiency

Conditions: Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects

Summary: the purpose of this research study is to: test the safety, tolerability, and pharmacokinetics (pk testing, the study of how the body absorbs, distributes, breaks down and eliminates a drug) of a single dose of the investigational study drug nbi-98854 in subjects with normal hepatic function or mild, moderate, or severe hepatic impairment.


Eligibility criteria:
inclusion criteria: * male or female, 18 to 75 years of age. * healthy volunteers must be in good general health. * subjects with hepatic impairment must be judged to be in stable condition. * subjects of childbearing potential must agree to use hormonal or two forms of nonhormonal birth control during the study. * female subjects must not be pregnant, given birth within 1 year of study start, or breastfeeding. * have a body mass index (bmi) of 18 to 40 kg/m2 (both inclusive). exclusion criteria: * report more than two alcoholic beverages daily or more than 14 alcoholic beverages weekly withing 7 days of study start. * have a known history of neuroleptic malignant syndrome. * have a positive human immunodeficiency virus (hiv) antibody result at screening or have a history of positive result. * have received an investigational drug within 30 days before screening or plan to use an investigational drug (other than nbi-98854) during the study. * have an allergy, hypersensitivity, or intolerance to tetrabenazine. * had a blood loss greater than or equal to 500 ml or donated blood within 56 days of study start. * have had previous exposure with nbi-98854.
data collection - of syncope tilt table testing study

Conditions: Orthostatic Hypotension; Reflex Syncope

Summary: to characterize the impact of orthostatic hypotension (oh) and reflex syncope on signals measured using a wearable cardiac monitor prototype device. to evaluate the relationship of signals measured from the wearable cardiac monitor prototype device with reported symptom severity of orthostatic intolerance per standard data collection, analysis, and questionnaires.

this is a non-randomized feasibility study that will enroll up to 50 participants that have undergone a previous autonomic reflect screen (ars) assessment and were either diagnosed with oh or reflex syncope, or considered to be control subjects for this study. a maximum of 20 subjects diagnosed with reflex syncope, a maximum of 10 subjects diagnosed with oh and a maximum of 10 control subjects will be enrolled. there will be one study visit per subject.

Eligibility criteria:
inclusion criteria: * willing and capable to provide informed consent * age 18 or above * no contraindications to undergo tilt table test, valsalva maneuver test, and deep breathing test (components of the ars assessment) * previously underwent a clinically indicated ars assessment without complications (including deep breathing, valsalva maneuver, and tilt table testing). previously diagnosed with oh, reflex syncope, or control subjects assessed as normal, based on the ars assessment. patient enrollment shall be based on the type of diagnosis. * willing to participate in one additional tilt table test, valsalva maneuver test, and deep breathing test (components of the ars assessment) exclusion criteria: * currently enrolled in another clinical trial that might interfere with data collection. * subject is pregnant or planning to become pregnant during the study * active implantable medical device, e.g. cardiac implantable electronic devices, bladder stimulators, diaphragm stimulators, implantable neuro stimulator, implantable active monitoring devices, implantable active drug administration devices, etc. * have a prosthetic cardiac valve or previously underwent cardiac valve surgery. * known allergy to materials used in the study (adhesive, ecg electrodes) * diagnosed with syncope due to cardiologic causes. * have had a myocardial infarction in the previous 90 days * have been diagnosed with tachycardia that requires medical treatment * experienced complications during previous clinically indicated ars assessment * are on medications that could affect autonomic function, if considered not safe or unwilling to hold such medications for at least four half-lives prior to testing (judged by the study principal investigator) * have any contraindication for tilt test, valsalva maneuver test or deep breathing test

Keywords: tilt table test, valsalva